Andrés Hugo Rossi

TL;DR: In this article, the authors evaluated SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naive or previously infected volunteers.

TL;DR: A novel set of recombinant flagellin with various deletions with an α-helical secondary structure that was as resistant to heat denaturation as the native protein constitutes a portfolio of TLR5-dependent candidate adjuvants for vaccination.

TL;DR: It is demonstrated that BLS immunization induces a preventive antitumor response that depends on mice TLR4, and BLS generates a therapeutic effect in mice inoculated with B16 cells, highly suggesting that B LS elicits its therapeutic effects acting on theTLR4 from B16 melanoma cells.

TL;DR: Data show that TLR4 signaling is necesary for the induction of a cytotoxic response but not for antigen cross presentation, and it is shown that immunization of wild type mice with the chimera BLS-OVA257–264 without adjuvants induced a strong OVA257-264-specific effector cytotoxicity response.

TL;DR: It is found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination.